Company: AEMD
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001683168-25-008271
Chunk: 32

Company: AETHLON MEDICAL INC
Filing Date: 2025-11-12
Form: 10-Q
Item: Item 1
Chunk 32
---
 accounts payable and other current liabilities, and $211,000 in prepaid expenses and other current assets, as well as $111,000 of lower
non-cash charges compared with the prior year, for a total offset of approximately $1,538,000.

NET CASH PROVIDED BY FINANCING ACTIVITIES.
Net cash provided by financing activities decreased by approximately $1,640,000 for the six months ended September 30, 2025. During the
current period, we raised $3,744,000, net of placement agent fees and offering costs, partially offset by approximately $9,000 used for
tax withholding on restricted stock unit settlements. In comparison, for the six months ended September 30, 2024, we raised approximately
$5,384,000, net of placement agent fees and offering costs, from the sale and issuance of common stock and warrants in connection with
a public offering, as well as the exercise of 3,750 Class A warrants and 36,000 Class B warrants. This amount was partially offset by
approximately $9,000 for tax withholding on restricted stock unit settlements, resulting in net cash provided by financing activities
of approximately $5,375,000. 

Material Cash Requirements 

We expect our clinical trial expenses for the
planned oncology trial in Australia to increase for the foreseeable future. Those increases in clinical trial expenses include the cost
of manufacturing additional Hemopurifiers.

In addition, we have entered into leases for our
headquarters, laboratory and manufacturing facilities. We expect our rent payments to continue to increase for the foreseeable future.

Future capital requirements will depend upon many
factors, including progress with pre-clinical testing and clinical trials, the number and breadth of our clinical programs, the time and
costs involved in preparing, filing, prosecuting, maintaining and enforcing patent claims and other proprietary rights, the time and costs
involved in obtaining regulatory approvals, competing technological and market developments, as well as our ability to establish collaborative
arrangements, effective commercialization, marketing activities and other arrangements. We expect to continue to incur increasing negative
cash flows and net losses for the foreseeable future. We will continue to need to raise additional capital either through equity and/or
debt financing for the foreseeable future.

We do plan to access the equity markets for additional
capital, however, there can be no assurance that we will be able to access such additional capital on favorable terms, or at all.

Our ability to raise